We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current 0DRV market cap is 333.77M. The company's latest EPS is NOK 0.6498 and P/E is 10.16.
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| NOK (kr) | NOK (kr) | NOK (kr) | NOK (kr) | NOK (kr) | |
| Total Revenue | 72.82M | 84.4M | 147.66M | 131.05M | 137.66M |
| Operating Income | -13.51M | -5.76M | 52.09M | 58.43M | 36.47M |
| Net Income | -14.19M | -6.39M | 83.12M | 46.38M | 32.86M |
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| NOK (kr) | NOK (kr) | NOK (kr) | NOK (kr) | NOK (kr) | |
| Total Assets | 84.47M | 77.61M | 221.91M | 284.11M | 319.04M |
| Total Liabilities | 32M | 31.13M | 25.58M | 39.27M | 34.3M |
| Total Equity | 52.47M | 46.48M | 196.33M | 244.85M | 284.74M |
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| NOK (kr) | NOK (kr) | NOK (kr) | NOK (kr) | NOK (kr) | |
| Operating | -15.19M | 3.97M | 46.93M | 74.97M | 58.09M |
| Investing | -2.7M | -1.1M | 64.85M | -11.56M | -12.43M |
| Financing | 18.97M | -3.24M | -3.26M | -3.16M | -1.92M |
| Market Cap | 333.77M |
| Price to Earnings Ratio | 10.16 |
| Price to Sales Ratio | 2.42 |
| Price to Cash Ratio | 1.37 |
| Price to Book Ratio | 1.17 |
| Dividend Yield | - |
| Shares Outstanding | 50.57M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 297 |
| 52 Week Change | 0.00% |
| 52 Week High | 6.60 |
| 52 Week Low | 6.60 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Biotec Pharmacon Asa |
| Address |
sykehusveien 23 tromso N-9294 |
| Website | https://www.arcticzymes.com |
| Industry | pharmaceutical biolog/vaccines (H23) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
